glp-1 without diabetes Semaglutide Shows Secondary Cardiovascular Prevention Benefits in Patients GLP-1 Drug Savings: A Complete

Lab Testing During Treatment To ensure the safe and effective use of GLP-1 receptor agonists, we recommend regular lab testing to monitor liver, kidney, pancreatic, blood sugar and micronutrients levels

The weight regain observed after the discontinuation of currently approved GLP-1 and GIP/GLP-1 receptor agonists represents an unmet need for anti-obesity regimens with sustained efficacy

JCI Insight

Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone

Like Contrave, phentermine should be taken along with diet and exercise

WHAT IS DIARRHEA